

Clinical and Payment Policy Update
Effective July 15, 2017
Investigational Treatment - Fractional Exhaled Nitric Oxide

PURPOSE: It is the policy of Superior HealthPlan that testing for fractionated exhaled nitric oxide (FeNO) is **investigational** for diagnosing and guiding the treatment of asthma, as there is insufficient evidence proving it more than or as effective as existing standards of care.

EFFECTIVE DATE: Service dates on or after July 15, 2017

Superior HealthPlan Program SCOPE: STAR, STAR+PLUS, CHIP, STAR+PLUS MMP, STAR Health, STAR Kids

Clinical Policy: Fractional Exhaled Nitric Oxide, Policy # CP.MP.103

<https://www.superiorhealthplan.com/providers/resources/clinical-payment-policies.html>

Procedure Considered Investigational

Effective for services on or after July 15, 2017, CPT 95012 is considered investigational, and will not be reimbursed unless an exception is noted in the Policy, and prior authorization for the medical necessity of the service is obtained prior to rendering the service.

| CPT Codes | Description |
|------------------|--|
| 95012 | Nitric Oxide expired gas determination |

ICD-10-CM Diagnosis Codes that Support Coverage Criteria – Not applicable

| ICD-10-CM Code | Description |
|-----------------------|--------------------|
| n/a | |